1. Overview
  2. All Stocks
  3. InMode Ltd

InMode (INMD.US) Price Target and Rating 2026/2027

15.08
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Share this analysis:

InMode Price Target 2026: Analysts See 7% Upside

The average price target for InMode is $16.17. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 7.23% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is InMode overvalued or undervalued?

InMode is currently fairly valued with a gap of 7.2% relative to the price target.


The current price is $15.08, which places InMode in the fairly valued category. The stock is considered undervalued when the price is below $14.55, and overvalued when the price exceeds $17.79.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For InMode, the fair value range lies between $14.55 and $17.79.


See the full price target analysis for InMode →

↑ Back to navigation

Analyst Ratings for InMode stock in 2026: Hold

7 analysts cover InMode. Analysts are mostly neutral — 71.4% recommend Hold. The average price target is $16.17, which gives an upside of 7.2% from the current price.

Consensus: Hold (3.43/5)
Strong Buy
1 (14.3%)
Buy
1 (14.3%)
Hold
5 (71.4%)
Strong Sell Sell Hold Buy Strong Buy
3.43 out of 5 based on 7 analysts
↑ Back to navigation

About InMode – Medicinprodukter

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel. Read more about the company

Key Figures for InMode

$ 859M Market cap
$ 375M Revenue
Medicinprodukter Industry
12.43 P/E
2.29 P/S
1.38 P/B
USA Listed on exchange
inmodemd.com Website
Healthcare Sector

What kind of stock is InMode?

Value stock

InMode is classified as a value stock with a value score in the top 15% of all stocks. The P/E ratio of 12.4 points to an attractive valuation.

Score Overview for InMode

💰 Value Score 85/100 (Very High)
⭐ Quality Score 48/100 (Neutral)
🚀 Momentum Score 64/100 (High)
📊 Total Score 65/100

⚠️ 1 red flag identified

Our analysis has identified 1 potential risk factor in InMode that investors should be aware of.

⚠️ Falling earnings: Quarterly earnings have fallen 31% year over year – the company's profitability is under pressure.

📈 Valuation

InMode trades at a P/E ratio of 12.4, which is below the market average and can point to an attractive price. The forward P/E is 11.2 (10% lower), which suggests the market expects rising earnings. The P/S ratio is 2.3. The P/B ratio is 1.4. The PEG ratio is 2.90 — above 2.0 suggests the stock is expensive relative to its growth rate.

💵 Profitability & Growth

InMode has a profit margin of 20.7% (excellent) and an operating margin of 12.8%. Return on equity (ROE) is 12.3% — solid return on equity. Return on assets (ROA) is 6.2%. The latest quarterly earnings grew -31.0% year over year — falling earnings.

🏦 Financial Health

The Piotroski score is 5 out of 9 — average financial health. Altman Z2 is 13.22 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 11.6% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 4.60%.

↑ Back to navigation

InMode Short Selling 2026: 4.6% Sold Short

Moderate short interest: 4.6% of the free float
Short % of free float
4.6%
Assessment
Moderate short interest
Short squeeze risk
Low
Data source
SEC
Updated daily
The stock has a moderate share of short selling. Between 2-5% of the freely traded shares are sold short, which is within the normal range for most stocks.

Data is updated daily based on official filings with the SEC.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
4.6%

↑ Back to navigation

When Does InMode Report Earnings?

The next earnings date for InMode is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of InMode 2026 – Signal: Strong Buy

Overall Technical Signal: Strong Buy

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 22, 2026.

Trend Analysis of InMode Ltd

InMode Ltd is in a short-term downtrend. The price of $15.06 is 0.8% below the 20-day average ($15.18). Medium term, the picture is positive: the price is 1.7% above the 50-day average ($14.81). Long term, the stock is 5.0% above the 200-day average ($14.35), which confirms a long-term uptrend.

Golden Cross: The 50-day average (14.81) is above the 200-day average (14.35), which is a classic bullish signal for InMode Ltd.

Is InMode Ltd overbought or oversold?

InMode Ltd has an RSI of 50.1, right in the middle of the neutral zone. There is no clear buying or selling pressure.

MACD Analysis for InMode Ltd

Daily MACD: MACD is positive (0.026), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is below the signal line (0.083) by 0.057, which suggests the positive momentum is fading – the trend could be turning.

Weekly MACD: MACD5 is positive (0.235), which indicates a broader bullish long-term trend. MACD5 is above the signal line (0.076) by 0.159, which confirms rising long-term momentum.

Overall MACD assessment: Both the daily and weekly trend are bullish (MACD positive). However, momentum shows signs of weakening on a daily basis. Watch whether the trend holds.

Risk Profile for InMode Ltd

InMode Ltd has an annual standard deviation of 32.6%, which classifies the stock as Balanced. There is some volatility, but the price is relatively stable.

Overall Technical Conclusion for InMode Ltd

Trend: Positive. The price trades above SMA50 and SMA200.

MACD trend (zero line): Daily bullish (0.026). Weekly bullish (0.235).

MACD momentum (signal): Daily falling. Weekly rising.

RSI: 50.1 – neutral.

Technical signal: Strong Buy

The price is in an uptrend (above SMA50/SMA200) and MACD is positive on both a daily and weekly basis. Trend and MACD trend confirm each other – the strongest technical buy signal.

↑ Back to navigation

Frequently Asked Questions About InMode stock in 2026

Should you buy InMode stock now?
Yes, the technical signal for InMode is currently BUY. InMode trades at $15.08 as of 8/22/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.026 with falling momentum (signal: 0.083); RSI is at 50.1 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $16.17 points to 7.2% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for InMode stock?
The average analyst price target for InMode is $16.17. The current price is $15.08, which gives an upside of 7.2%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $14.55 and $17.79.
Is InMode a dividend stock?
No, InMode does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of InMode stock?
InMode is rated as a stock in the risk category Balanced. the annual standard deviation is 32.6%, which classifies the stock as Balanced.
Is InMode overvalued?
InMode is considered fairly valued – the price is close to the analyst price target. InMode has the following valuation ratios: a P/E ratio of 12.4 (moderately valued), a P/S ratio of 2.3, a P/B ratio of 1.4. The stock trades close to the analyst price target and is considered fairly valued.
Is InMode overbought?
No, InMode is not overbought. RSI is at 50.1 (neutral zone). The technical indicators show: RSI is at 50.1 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.6% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next InMode earnings report?
The date of the next earnings report for InMode has not been published yet. Check the company's investor calendar for updates.
Is InMode shorted?
Yes, InMode is shorted with 4.6% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying InMode stock?
There is currently no registered insider trading for InMode.
Is InMode a good stock?
Based on our total score, InMode is rated as a good stock with a total score of 66 out of 100. The stock scores above average on value, quality and momentum – it is among the top 34% in our database. The score is made up of Value: 85/100, Quality: 48/100, Momentum: 64/100. In addition: technical signal: Strong Buy. Whether InMode is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for InMode stock?
The outlook for InMode based on current data: the average analyst price target is $16.17 (+7.2%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 12.4 (low – a possible value stock). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is InMode stock moving?
InMode is stable right now. The technical indicators show: the price is close to the 20-day average. For the latest context, see our technical analysis, insider section and news overview above.
How high can InMode go?
The average analyst price target for InMode is $16.17, which corresponds to a potential gain of 7.2% from the current price of $15.08. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can InMode fall?
We lack enough history to give a specific floor for InMode. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does InMode do?
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.... The company belongs to the Healthcare sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate InMode as an investment.
Did InMode raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from InMode. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is InMode making money or losing money?
Yes, InMode is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 20.7% — which is excellent. The operating margin (profit before interest and taxes) is 12.8%. At a P/E ratio of 12.4, you currently pay 12.4 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can InMode go bankrupt?
The bankruptcy risk of InMode is rated as low. Altman Z2 (a model for assessing financial distress) is 13.22 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 12% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does InMode have a lot of debt?
No, InMode has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 12%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Explore More